Mathematical models and numerical methods have emerged as fundamental tools in the investigation of life sciences. In particular, this is the case of medical devices as cardiovascular drug eluting stents where experimental/clinical evidence may often be very expensive and extremely variable. We present here a complete overview of mathematical models and numerical methods applied to the modelling of drug eluting stents and of their interaction with the coronary arteries. This is a challenging task because it involves mechanics, fluid dynamics and mass transfer processes. In particular, we will focus on the importance of the interplay between all these factors to determine the efficacy of the device.
Introduction
A stent is a small mesh tube that is inserted permanently into a stenotic artery. The stent restores the original value of the arterial section to ensure the physiological 1 flow rate. One of the problems caused by the stent insertion is the re-narrowing of the treated vessel. To overcome this phenomenon drug-eluting stents (DES) have been recently introduced. Referred to as a coated or medicated stent, a DES is a normal metal stent that has been coated with a pharmacologic agent (drug) that is known to interfere with the process of restenosis (reblocking). However, the design of such devices is a very complex task because their performance in widening the arterial lumen and preventing further restenosis is influenced by many factors such as the geometrical design of the stent, the mechanical properties of the materials and the chemical properties of the drug that is released. Mathematical models and numerical simulation techniques are appropriate to study such phenomena with the aim to be used as a predictive tool for the effective design of drug eluting stents.
We present in this work a complete review of the mechanics, fluid dynamics and drug release models developed by the authors for the numerical simulation of drug eluting coronary stents. In particular, we will focus on the importance of the interplay between several factors, as the mechanical action exerted by the stent on the wall to determine the final configuration of the artery, as well as the interaction of the blood flow with the drug release process. Indeed, these topics have been already analyzed separately, see [12, 16, 17] , but the study of their interaction is still rather new in literature. For example, since the role of the drug is to heal the artery after the implantation of the stent, most of the computational studies on the efficacy of DES have focused their attention on the transport of the drug into the arterial walls, we refer to [15] and references therein for some examples. In most cases, the blood flow is assumed to have a minor influence on the distribution of the drug into the walls. In particular, it is common to consider that the arterial lumen acts as a perfect sink with respect to the drug concentration, because it is rapidly transported away from the location of the stent. Recently, the analysis pursued in [2] suggested that this assumption is not really justified. Indeed, the drug that is apparently lost in the blood stream significantly affects the drug deposition in the portion of the arterial walls downstream to the stent. In this work, we aim to better understand the interaction of the blood flow and the drug deposition into the artery by means of mathematical models and numerical approximation methods, because experimental/clinical evidence for the problem at hand is expensive, extremely variable and provides indirect data that is difficult to correlate with
the phenomena we aim to analyze. By consequence, we propose and collect here suitable mathematical models for the stent expansion, the description of hemodynamics and drug release and we focus on their interaction in order to describe the 2 behavior of realistic drug eluting stents.
The outline of the paper is as follows: in section 2 we introduce the mathematical modelization of the problem at hand, in particular the mechanical stent expansion (section 2.1), the fluid dynamics (section 2.2) and the drug release (section2.3).
In section 3 we describe the numerical methods used for the discretization of the proposed problem and in the end in section 4 we present a case study starting fron realistic geometry and data.
Mathematical models
The proposed analysis of the stent expansion and the drug elution is made of two consecutive phases. During the former one, a stent is expanded into an atherosclerotic coronary artery. Then, in the latter phase, the configuration of the artery and stent are used for the analysis of the fluid dynamics and drug release.
Mechanical analysis of the stent expansion into a coronary artery
A previous study [8] showed that the stent expansion modelling techniques influence the output in terms of arterial wall stresses and strains. Hence, for a more reliable description of the deformation induced in an artery by stenting, it is necessary to model the inflation of a polymeric deformable balloon. Nevertheless, the simulation of the stent-balloon expansion in a coronary artery is not a trivial problem: the balloon is typically folded around the catheter and blocked by the crimped stent. Accordingly, the unfolding process requires the solution of a very complex contact problem with large sliding between the surfaces of the balloon itself, the stent struts, the plaque and the inner arterial wall. In this work, we use a simplified model constituted by a balloon, a stent and a coronary artery that are shown in figure 1 (left) in their initial configuration. The analysis is performed in the frame of classical continuum mechanics under the hypothesis of large strain conditions.
In particular for the balloon we consider an initial configuration obtained deflating the full expanded model, developed according to the manufacturer information.
In this way, as shown in section 4.1, it is possible to describe the characteristic behavior of a semi-compliant balloon and in particular the strong stiffening at higher pressure, even using an isotropic, linear-elastic material model. Assuming that the elastic strain is small and that the rate of deformation can be regarded as the total strain rate measure, namelyε = sym(L) where L is the velocity gradient in the current configuration, the material constitutive model of the implanted baloon, 3 conveniently written in the incremental form, reads:
whereσ is the increment of the Cauchy stress tensor with the elastic tensor D depending only by the Young's modulus E and the Poisson's ratio ν. Furthermore, also the contribution of the average incremental rigid body rotation of the material has to be taken into account. A different approach may be found in [7] .
A realistic geometry is considered for the stent model, which is assumed to be made of 316L stainless steel. The steel is modelled as a homogeneous, isotropic, elasto-plastic material through a Von Mises plasticity model. Assuming again the elastic strain small and the rate of deformation as total strain rate measure, it is possible to describe the inelastic behavior of the stent using the additive strain rate decomposition:ε =ε el +ε pl whereε el andε pl are the elastic and plastic components of the total strain rateε, respectively. Accordingly with classical plasticity theory, the mathematical description of the stent can be given by the following incremental constitutive equation and associative flow rule:
The limit function is
where J ′ 2 is the second invariant of the deviatoric stress tensor s = σ + pI, with p = −1/3tr(σ ) the equivalent pressure stress and I the second order identity tensor and K(α) is the linear isotropic hardening function:
The constant σ y is the yield stress and K is the hardening modulus. The quantitȳ ε pl is the equivalent plastic strain given by:
Finally, the consistency parameterλ has to satisfy the following Kuhn-Tucker com-4 plementary conditions:λ
and the consistency requirementλḞ(σ ) = 0.
Concerning the arterial wall, we remind that it is a complex structure that consists mainly in three concentric layers: the intima, the media and finally the adventitia. These layers are principally composed of collagene fibers and elastin that
give properties of anisotropy and incompressibility. We refer to [10] and the reported references for a more detailed description of the biological aspects and of the advanced computational models available in literature.
In our simplified model, the coronary artery is described as a hollow cylinder partitioned into three layers of equal thickness, representing the intima, the media and the adventitia. A bond of perfect adhesion exists between each pair of vessel layers. For describing the mechanical behavior of each layer, we use a hyperelastic isotropic constitutive model based on a reduced polynomial strain energy density function U , of sixth order:
whereĪ 1 is the first invariant of the Cauchy-Green tensor
whereλ i are the principal stretches and J is the total volume ratio.
The model is not able to take into account residual stresses present in the loadfree artery configuration and the overstretch of the non-diseased part of the lesion due to supraphysiological loading induced by balloon expansion: we refer to [7] for a deeply discussion of these aspects. Moreover, in our work the plaque is not considered. This choice was motivated by the observation that the lack of experimental data about the material properties as well as the poor knowledge of the atherosclerotic plaque growing process make totally arbitrary any modelling choice. It is clear that the availability of more information about the mechanical behavior and the use of more refined models of atherosclerotic tissue could give more precise information about the effects of the stenting process. However, we believe that even the simplified model herein introduced does not play down our 5 methodology.
To reduce the computational time we study the expansion of only a single stent unit, i.e. a closed axial stent segment. A previous analysis [8] showed that this choice is sufficient to represent the mechanical behavior of the stent. Accordingly, we perform the analysis on a portion of the coronary artery whose length is sufficient to avoid boundary effects. The dimension of the balloon is coherently set, conserving the stent/balloon length ratio usually adopted in the practice.
As regards the boundary conditions of the model, the outer cross sections of the artery indicated with Γ n,w in figure 1 (left) are constrained in the longitudinal direction to simulate the fact that the considered model is not a stand-alone segment but is part of a whole coronary artery. Furthermore, in a axial section located in the center of the artery, three nodes forming the vertexes of an equilateral triangle are constrained in the tangential direction to avoid the rotation of the structure.
These conditions allow the radial expansion of the artery. As regards the stent,
we apply boundary conditions which constrain in the longitudinal and tangential 
Fluid dynamics models in the lumen and in the arterial walls
Thanks to the assumption that coronary arteries treated with cardiovascular stents are large enough to apply a Newtonian model for blood rheology, we consider the Navier-Stokes equations for the fluid dynamics in the arterial lumen. We denote
with Ω f a portion of a coronary artery where we set up our analysis. This is the cylindric channel deformed by the introduction and the expansion of a stent, as described in the previous sections. We denote with Γ in and Γ out the proximal and distal sections since they coincide with the inflow and outflow sections of the domain Ω f . The remaining part of the boundary of Ω f can be subdivided in two parts, 6 the interface with the arterial wall and the stent. The former is denoted with Γ and the latter with Γ s, f . In conclusion we obtain figure 1 (right) . Finally, we denote with n f the outward unit normal vector on
To analyze the drug release process on a significant time scale we need to consider a time period containing several thousands of heartbeats. This is a challenging difficulty for the drug release model, which is common to all ordinary/partial differential equations with highly oscillating coefficients or forcing terms. To override this difficulty at a preliminary level, we consider the mean value of the pulsatile blood flow and simultaneously we assume that the arterial walls are rigid. Then, the blood flow is provided by the steady Navier-Stokes equations,
where v f is the blood flow velocity, p f the corresponding pressure and µ the blood dynamic viscosity. Equation (2) is complemented by suitable boundary conditions specifying a parabolic inflow profile, v f = v in on Γ in , perfect contact between the blood, the arterial walls and the stent, v f = 0 on Γ ∪ Γ w , and zero traction force at
We remind that the flow is not restricted to the arterial lumen. Indeed, blood plasma filtrates with a velocity v w from the inner to the outer part of the arterial walls under the action of blood pressure. As observed in [23, 13, 17] this phenomenon is extremely important for the transfer of large molecules (as for instance low density lipoproteins) from the blood flow to the arterial walls, because the diffusivity of such molecules is extremely low. For smaller molecules, such as oxygen but also some of the drugs that are released from stents, the mass transfer form the lumen to the arterial walls is diffusion dominated rather than governed by advection. This is shown in [23] by means of dimensional analysis. For this reason, in this study we neglect the advective phenomena into the arterial walls (v w = 0) and we refer to [13, 17] for a detailed description of the corresponding models.
A mathematical model for drug release
We assume that the drug released by the stent behaves as a passive scalar. This statement holds true under the assumption that the drug does not react with the arterial walls. This is a zero-level simplification of a number of chemical phenomena that involve the drug as a ligand and suitable sites of the extracellular matrix as 7 receptors. It is well known that such phenomena may strongly influence the distribution of the drug into the arterial walls, as discussed in [22, 24] . However, it is not definitely clarified how to translate these phenomena into equations and how to feed them with parameters. By consequence, our drug release model features just one chemical specie, the drug, that is governed by standard advection-diffusion equations. Furthermore, the drug we will consider in the numerical experiments is heparin, a relatively small molecule with non negligible diffusive properties. Then, for the interaction of the mass transfer in the lumen and in the arterial walls we address the model described and analyzed in [19] for the transport of oxygen. As already mentioned, in this case the advective phenomena into the arterial walls are neglected. Concerning the coronary artery, we make here a simplification of the complex multilayered structure of the wall, more precisely we assume that the arterial wall is an homogeneous medium, whose physical properties are, for simplicity, the ones corresponding to the intermediate layer, namely the media. This assumption can be easily removed at the computational level because the deformed configuration of the three layers of the artery is provided by the mechanical analysis described in section 2.1. However, this improvement becomes troublesome in practice, because of the lack of reliable data on the transport properties of each layer with respect to the drug. To our knowledge, only average values for the complete arterial wall are available, we refer to [14] for the case of heparin. In this setting, let Ω w be the truncated portion of the arterial walls corresponding to Ω f .
We denote with Γ a the interface of the arterial wall with the outer tissue, with Γ n,w the artificial sections originated by the truncation of the artery and with Γ s,w the interface of the stent with the arterial wall. Moreover, let n w be the outward unit normal vector relative to Ω w . Furthermore, contrarily to the assumptions adopted for the fluid dynamics, we consider the time dependent case, because the drug release process is intrinsically transient and it dies out in a long but finite time. Then, the governing equation for the drug concentration read as follows,
together with a condition prescribing the initial state of the concentration in the blood stream and into the arterial walls, c * (t = 0) = 0 in Ω * and suitable boundary conditions. For the arterial lumen, Ω f , on the inflow boundary we prescribe c f = 0 on Γ in since the blood does not contain drug proximally to the stent. Assuming that the outflow boundary is far enough to the stent, we can neglect any diffusive 8 effects across this section and set ∇c f · n f = 0 on Γ out . Also for the arterial wall we prescribe ∇c w · n f = 0 on Γ a ∪ Γ n,w . According to [19] , for the transmission conditions between Ω f and Ω w we take into account the endothelium, a single layer of cells impermeable to the blood flow. The endothelium is modelled as a membrane at the interface between the lumen and the arterial walls, corresponding to Γ, having a permeability P with respect to the transfer of drug. This model allows to take into account the possible shear-dependent behavior of mass flux through the endothelium. This is an interesting problem that has been addressed in [20] and [21] for oxygen and albumin transport respectively. A similar discussion can be also addressed for the diffusion parameter in the blood flow, namely D f .
Indeed, according to [26] the rotation of red blood cells due to flow vorticity may lead to augmented transport properties. However, the intrinsic difficulty of this studies is to quantify the dependence of the endothelial permeability and blood diffusivity with respect to the fluid dynamics quantities as shear stresses or shear rates. Since to our knowledge there are no available data on this dependence in the case of drugs, we do not include this feature in our model and we assume that the permeability P and the diffusivity D f are constant and uniform. Then, the coupling between equations (3) is provided by the following conditions,
We observe that these conditions can be rewritten as follows,
The latter formulation has the advantage to be symmetric with respect to the lumen and the arterial walls. As shown in [19] this represents an advantage both for the analyis and the numerical approximation of the coupled problem.
Finally, particular attention should be dedicated to the condition on the interface between the stent and the lumen, because it is primarily responsible to determine the drug release rate. We remind that DES for cardiovascular applications are miniaturized metal structures that are coated with a micro-film containing the drug that will be locally released into the arterial walls for healing purposes. The thickness of this film generally lays within the range of microns. Owing to the fact that the stent coating is extremely thin, we apply the model proposed in [25] where it has been derived the following formula for the release rate,
being c 0 s the initial drug charge of the stent that is equal to the unity in the undimensional setting for the concentration. Given the thickness of the stent coating, ∆l, and its diffusion parameter, D s , the scaling function ϕ(t) is defined as follows,
The derivation of (5) is similar to the procedure that leads to the well known Higuchi formula [9] , that provides the drug concentration c s into a semi-indefinite planar slab (with axial coordinate z) representing the stent coating, under the assumption that the external medium acts as a prefect sink,
However, equation (6) has the advantage to avoid the restrictive assumptions of Higuchi formula (7). Owing to (5), the boundary condition on Γ s, f and Γ s,w for equation (3) turns out to be the following Robin type condition,
The initial/boundary value problems relative to equations (2) and (3) are now ready to be approximated by means of suitable numerical methods.
Numerical methods

Numerical simulation of the stent expansion
The strong nonlinearity of the problem, due to material and contact constraints, suggested the use of an explicit dynamics analysis procedure for its solution in the frame of the finite element method. In particular, the commercial code ABAQUS/ Explicit v. 6.4 is employed. The space dependence of the mechanical model is discretized with eight-node iso-parametric brick elements with reduced integration for the stent and the artery, while we adopt four-nodes or three-nodes membrane elements with reduced integration to discretize the balloon.
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The treatment of the dynamic problem is based upon the implementation of an explicit integration rule together with the use of lumped element mass matrices. In particular the explicit central difference integration rule is used for integrating the motion equation. Let u ∈ R 3 be the displacement of each element node.
The known values of the accelerationü from previous increment (n), of the velocityu from previous mid-increment (n + 1/2), as well as of the time increment ∆t at the current (n + 1) and the previous (n) increment, are used for calculating velocity and displacement at the current interval:
If diagonal element mass matrices M are used, it is straightforward to calculate the acceleration at the beginning of the increment simply inverting the dynamic equilibrium equation:
with F n and P n the external applied forces and the internal element forces, respectively. Peculiar attention has to be paid to the initial condition. The central difference operator is conditionally stable, and the stable time increment ∆t has to satisfy the relation:
where ω max is the highest eigenvalue in the system. If small amount of damping is introduced to control high frequency oscillations, the time increments have to satisfy:
with ξ the fraction of critical damping in the highest mode.
Since the aim of the analysis is to define a stented artery configuration in the steady state condition,a quasi-static analysis is performed. Hence, we increase the density of the materials, we smooth the application of loading and set the time step of the simulations to 1 s, in order to model the process in the shortest time period in which inertial forces remain insignificant. This hypothesis is verified evaluating that the ratio between kinetic and internal energies of the model does not exceed the value 5%, as suggested by the ABAQUS manual.
To take into account the contact between different parts, we use the contact pair algorithm proposed in ABAQUS/Explicit, see ABAQUS version 6.5 Online Documentation, and we adopt a kinematic predictor/corrector contact algorithm to strictly enforce contact constraints (no penetrations are allowed), coupled with a finite sliding approach to account for the relative motion of the two surfaces forming the contact pair, and an exponential pressure-overclosure relationships to specify the interaction behavior.
Numerical simulation of the fluid dynamics and of the drug release
As already seen, our drug release model involves the coupling of the blood flow equations with an advection-diffusion problem, namely equations (2) and (3). In these models, the advection-diffusion equations depend on the fluid dynamics through the advective field. Hence the fluid dynamics problem is solved at a first step, and then we solve the mass transfer problem.
For the space discretization of the space-dependent partial differential operators, we apply the finite element method. In particular, for what concerns the Navier-Stokes equations we have adopted a linear approximation based on P 1 − P 1 elements that have been stabilized with respect to pressure/velocity coupling and to a high local Reynolds number by means of the interior penalty scheme proposed in [3] . Furthermore, we have adopted the classical Picard's scheme for the treatment of the nonlinear term.
Concerning the advection-diffusion equations we apply P 1 elements for the space discretization and implicit Euler scheme for the approximation of the time dependence. We observe that equation (3) is advection dominated in Ω f . As it is well known, finite element techniques could be inaccurate when facing such problems and resorting to a stabilization technique becomes mandatory. Different strategies can be pursued in this regard, we apply again interior penalty schemes, developed in [4] for advection-diffusion-reaction problems and also applied to coupled problems in [5] .
A further difficulty is related to the fact that we consider phenomena that take place both into the blood flow and into the arterial tissues. In particular, the coupled problem given by equations (3) and by the matching conditions (4) can not be reformulated as a problem governed by a unique differential operator on a single domain. For this reason, we focus our attention on suitable iterative methods in order to split (3)-(4) into a sequence of independent problems. To this purpose, a general theory is discussed for instance in [18] , for the case of linear symmetric problems. However, the presence of a non negligible advection term makes our case to be governed by a strongly unsymmetric operator into Ω f . For this reasons, we refer to [19] where a case equivalent to (3)- (4) 
An iterative splitting algorithm for the coupled problem of drug release
To address in detail the iterative splitting method for the drug release problem, we refer to the time-discrete setting. To this purpose, we subdivide the time interval [0, T ] in N time steps t n and n = 1, . . . , N, where ∆t n = t n+1 − t n > 0 is possibly non uniform, and use backward Euler finite difference schemes. Since all the relevant equations deal only with unknowns evaluated at the time step t n , for notational convenience we drop the index n. The time index will be explicitly indicated only when referring to a time step different than t n . Then, problem (3)- (4) complemented with boundary and initial conditions can be reformulated as follows: for any time step t n , find a sequence c k f , c k w such that,
problems whose well-posedness in the classical Sobolev spaces
can be easily proven by means of the Lax-Milgram lemma, which also ensures the existence and uniqueness of solutions at the discrete level. The well posedness at the discrete level is maintained also when the Galerkin approximation of problem (8) is stabilized by means of the interior penalty scheme. We refer to [4] for a complete analysis of this method. Finally, it is possible to prove the convergence of the sequence c k f , c k w to the solution of the coupled problem, denoted with c f , c w . We remind the main result in the following proposition. (8) and (9) is convergent. Let e k * = c * −c k * be the iterative splitting error with * = f , w, where c * is the solution of the coupled problem (3)-(4) and c k * is the sequence generated by (8) and (9) . More precisely we have:
Proposition 1 (Convergence of the iterative splitting method) The iterative method defined by equations
lim k→∞ c * − c k * H 1 (Ω * ) = 0 with * = f , w.
A similar result holds true at the discrete level for both the Galerkin and the interior penalty stabilized discretizations. The convergence rate may depend on the physical data but not on the mesh size h.
Proof. By subtracting (8)-(9) from the equations of the coupled problem, namely (3)- (4), we obtain the governing equations from the splitting error e k * . Their weak formulation reads as follows,
being a f (·, ·) and a w (·, ·) the bilinear forms associated to problems (8) and (9) without the contributions of the coupling terms, which have been explicitly reported.
It is easily seen that these bilinear forms are coercive with respect to the standard H 1 -norm on Ω * with suitable constants α * that may depend on the diffusivity parameter D * . Choosing v * = e k * , * = f , w and exploiting the coercivity and the Cauchy-Schwarz inequality we obtain,
Owing to the trace theorem there exists a constant C * such that v 2
The application of this inequality into the equations above, together with the simplifying assumption that P is a constant parameter, leads to the following results,
that can be combined in order to obtain,
Together with the trace inequality, this proves the desired result.
Finally, we observe that the proof can be immediately extended to the case of the Galerkin discretization method. Since the constants that determine the error reduction factor in the final inequality do not depend on the discretization method, we conclude that the convergence rate is always independent on the discretization parameter h. We also observe that the introduction of the interior penalty stabilization term in the discrete equation for c f does not prevent the convergence of the iterations. Indeed, the proof remains unchanged if we replace to a f (·, ·) the following stabilized bilinear form,
being F i h the collection of all the internal edges (d = 2) or faces (d = 3) e of the computational mesh on Ω f ⊂ R d , whose normal vector and (d − 1)-dimensional measure are denoted with n e and h e respectively.
Remark 1 (Robustness with respect to singularly perturbed problems)
We observe that the proof of proposition 1 suggests that the iterative method may not converge in the case of singularly perturbed problems, namely when D * → 0. In this case the coercivity constants vanish and correspondingly the estimate of the error reduction constant at each iteration approaches the unity. This is not an intrinsic problem of the iterative method. In fact, the proof can be easily adapted to the case of singularly perturbed problems by virtue of the introduction of the energy norm,
We notice that the bilinear forms a * (·, ·) are coercive with respect to this norm, uniformly with respect to the diffusivity parameter D * , namely a * (v, v) ≥ |||v * ||| 2 for any v ∈ H 1 (Ω * ). The proof of proposition 1 can be straightforwardly adapted to this case. Indeed, starting from the splitting error equations we easily obtain that,
Combining these inequalities and summing up from k = 1 to k = M we get,
The convergence of the sequences c k f and c k w is obtained passing to the limit for M → ∞. However, in this case the convergence rate of the iterations can not be explicitly characterized.
A-priori adapted time stepping
The drug release form the stent is a transient process that features a very fast initial phase that progressively slows down until almost all the drug has been delivered.
The dynamics of the release rate with respect to time can be approximated by means of the Higuchi formula, namely equation (7), which provides an explicit estimate for the flux of drug outgoing the stent,
This formula, which is exact for the limit case t → 0 but inaccurate for long time periods, provides an effective way to adapt the time advancing step to the transient release process, as discussed in [25] . For simplicity, we set up an adaptivity strategy based on the increment of the amount of drug that is released from the stent to the arterial walls. More precisely, we aim to find a suitable sequence of time steps, t n , such that a constant fraction of the total amount of drug is released in each time slab. We notice that this problem can be solved exactly in the framework of the Higuchi model. In particular, let η be the constant fraction of drug that we aim to release at each time step. Let us introduce a uniform partition of [0, 1] into sub-intervals of length η, such that N := 1/η is an integer, for simplicity. Cor-16 respondingly, we define the sequence f n = nη with n = 0, . . . , N. The time steps that we look for, correspond to the mapping of the sequence f n into the interval [0,t e := (π∆l 2 )/(4D s )] by means of the incremental version of equation (7),
We notice that ∆t n grows linearly with respect to η. After N steps, this scheme reaches the time t e where all the drug should have been delivered, according to the inexact Higuchi model. Then the time step can be maintained constant and equal to ∆t N . For a time interval of 1 day, the numerical experiments presented in [25] show that this a-priori adapted time stepping ensures that the amount of drug delivered in each time slab is almost constant also in the case of the release model (6) applied in our case. Reminding that our time discretization scheme is only first order accurate, the key point is to choose a suitably small increment, η, that ensures an effective compromise between computational efforts and accuracy, in particular mass conservation.
A case study: influence of the arterial stent positioning on blood flow and the drug release
We aim to study the interaction of the blood flow with the drug released from the stent. This task is particularly challenging because the complex geometry of the stent highly perturbs the local flow and this significantly influences the path of the drug released into the lumen. We split this analysis in three parts. First of all we focus on the structural mechanics generated by the stent expansion; secondly we analyzed the fluid dynamics, trying to put into evidence the main features of the flow around the stent. Lastly, we study how this flow influences the drug release.
Analysis of the stent expansion
The stent used in this study resembles the coronary Cordis BX-Velocity The length of the unit of the stent considered in the analysis is 3.62 mm, the inner radius 0.6 mm and the thickness 0.14 mm. A mesh of 14951 8-node cubic element is generated. For the material parameters we refer to [1] where the Young's modulus is E=193 GPa, the Poisson's coefficient ν=0.3 and the yield stress σ y = 205 MPa; we take into account the degradation of the hardening modulus, varying from K=1500 MPa and K=97 MPa, using the ABAQUS option of defining a a linear piecewise isotropic hardening.
The balloon is designed with a radius of 1. figure  4 (f) we notice that the parameters useful to quantify the interaction between the stent and artery and consequently the efficacy of drug elution may be:
1. the metal to artery ratio in the expanded configuration that measures the artery surface covered by the stent and hence of the area prone to a direct diffusion of the drug. In this case it is equal to 18%.
2. the foreshortening effect that is a measure of the contraction of the stent during the expansion and hence it gives an information about the length of the area interested by the drug release process..
3. the dogboning effect that quantifies the irregular expansion of the stent (grater in the external part than in the central one) and hence it is related with the irregularity of the artery internal surface that may influences the fluid dynamic phenomena.
In figure 5 are also reported radial, circumferential and axial Cauchy stress components: even if not directly used in the following analysis, they may be useful to better understand the effects of stent-balloon expansion on the artery configuration and eventually to highlight local conditions particularly unsafe.
Finally, we recall that refinements of the stent expansion geometrical and constitutive models will be useful for a more detailed and precise description of the process and hence for more precise initial conditions of blood flow and the drug deposition problem. 
Analysis of the fluid dynamics around the struts
The lumen and the wall of the artery are subdivided with Gambit (ANSYS Inc., Canonsburg, PA, USA) into 1,637,336 and 1,118,420 tetrahedra respectively. In order to obtain an accurate resolution with a reasonable computational cost and memory storage, we have applied a nonuniform spacing for the mesh generation.
In particular, the central part of the domain have been subdivided by means of variable size elements, particularly refined around the stent.
Looking at the Cordis BX-Velocity stent, it is possible to identify two kinds of structures, the struts and the links. The former are twisted rings that provide the circumferential strength of the stent, while the latter are tiny connections along the longitudinal axis between subsequent struts.
An important feature of the struts is to be twisted in the circumferential direction. For this reason, the blood flow hits the struts with different angles. The preliminary results obtained in [6] suggest that the flow pattern downstream the struts may be substantially different from the well-known flow after a backward facing step that corresponds to the ideal case of a perfectly circular ring that is orthogonal to the flow. This conjecture is confirmed by the fluid dynamics simulations. Indeed, in figure 6 we visualize the streamlines of the blood flow around the stent. This picture shows that we deal with a fully three dimensional flow with recirculations, vortexes and secondary motions. For instance, we observe that the vortex induced by the presence of the link on the top left corner is stretched and absorbed in the main stream on its right side. This suggests that this vortex is not only characterized by a planar rotating flow but an out of plane motion is present.
This secondary motion generates the displacement of the fluid form the center of the vortex to the extrema and the fluid is thus cast out the vortex into the main stream.
In conclusion, there is evidence that the interaction between the stent and the blood stream generates very complex flow patterns where the recirculation zones downstream the obstacles interact with the main stream. By this way, the fluid that was at some time trapped into a recirculation may join the high speed flow. We will see in the next section that this behavior has important consequences on the drug release process.
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As already mentioned, we simulate the release of heparin. According to the experimental investigations presented in [14] , this corresponds to set D f = 1. This means that a wide portion of the endothelium, which is often severely injured by the stent implantation, is exposedto a non negligible drug concentration. When the drug has anti-proliferative properties, the re-endothelialization process mey be slowed down. This seems to be one of the major drawbacks of DES, and it should be further investigated.
Concerning the struts, the accumulation of drug is unexpectedly prominent upstream with respect to the blood flow. High concentration levels take place where the struts are highly curved and their curvature is convex with respect to the blood flow. This is in contrast to the results obtained in [2] , but can be explained observing that blood transports the drug downstream to the location where it has been released. The accumulation of the drug takes place where this effect is hindered by the convex stent pattern with respect to the blood flow.
The results reported in figure 7 (right) suggest that part of the drug released into 21 the lumen is absorbed by the wall. However, depending on the sign of the quantity P(c f − c w ) of equation (4), the opposite process is simultaneously happening, because the drug concentration in the wall is much higher than the one into the lumen in the surroundings of the interface of contact between the stent and the artery.
Indeed, the interface Γ between the lumen and the walls can be subdivided into a region where the drug is absorbed into the wall and the complementary region where the drug is released by the wall and definitely lost into the blood flow.
This balance can be analyzed by means of more quantitative results. After 1 hour from the stent implantation, almost all the drug has been released. The contact interface between the stent and the walls ensures that 15% of the total amount of drug is released into the walls. However, more than a half of this fraction is simultaneously transferred into the lumen because of the negative concentration gradient between the lumen and the walls. Then, for the case analyzed here, the drug released into the lumen does not significantly contribute to the permanent drug deposition into the arterial wall. However, to come up to a general conclusion, further investigations are mandatory.
Conclusions
We have analyzed the interactions between the stent shape and positioning, the blood flow and the drug release from a stent, showing that a 3-dimensional analysis of the problem accounting for the complex geometry of the stent is mandatory to capture the phenomena into play. In this setting, we have studied the contribution of the drug released into the blood flow with respect to the efficacy of drug deposition and penetration into the arterial walls. 
